多西他赛联合基质金属蛋白酶抑制剂SB-3CT 对前列腺癌移植瘤生长的影响
潜力， 符翠莉， 李锡明， 黄桂海， 林俊浩， 李伟 - 中国癌症防治杂志, 2020 - zgazfz.com
… Identification of mechanisms of resistance to treatment with abiraterone acetate or
enzalutamide in patients with castration鄄resistant prostate cancer(CRPC)[J].Cancer, 2018,124(6):…
enzalutamide in patients with castration鄄resistant prostate cancer(CRPC)[J].Cancer, 2018,124(6):…
去势抵抗性前列腺癌的治疗进展
王晴， 杜君， 杨庆 - 中国肿瘤临床, 2016 - cjco.cn
… treatment of castration-resistant prostate cancer remains challenging, and the underlying
mechanisms of this cancer have yet to be identified… Efficacy and safety of enzalutamide versus …
mechanisms of this cancer have yet to be identified… Efficacy and safety of enzalutamide versus …
循环肿瘤标志物在前列腺癌研究中的新进展
李高翔， 杨云杰， 戴波 - 中国癌症杂志, 2017 - china-oncology.com
… the circulating tumor biomarkers detection methods and relevant … prostate cancer with the
CYP17 inhibitor abiraterone acetate[… AR-V7 and resistance to enzalutamide and abiraterone in …
CYP17 inhibitor abiraterone acetate[… AR-V7 and resistance to enzalutamide and abiraterone in …
[PDF][PDF] 三阴性乳腺癌精准治疗研究进展
邵笛， 余天剑， 邵志敏 - 中国普通外科杂志, 2023 - zpwz.net
… mechanisms and microenvironmental characteristics. Based on the intrinsic features of TNBC
and the current treatment … 用 于治疗TNBC 的疗效.enzalutamide 应用于AR 阳性 TNBC 患者…
and the current treatment … 用 于治疗TNBC 的疗效.enzalutamide 应用于AR 阳性 TNBC 患者…